Category: Money tips Release Date: 2006-02-19
Source: Big Rich Investment
With the rapid economic growth, population aging and many other factors that will drive the rapid development of domestic pharmaceutical market, pharmaceutical, high-growth business as a whole the trend was clearer. Pharmaceutical distribution industry, network value is being recognized by the market, pharmaceutical distribution companies the size of the larger network of more widely, resulting in value-added services, the more obvious benefits. Stock Recommendation: G Fosun (600,196), the company owns China's largest drug distribution companies controlling 49% stake in Sinopharm. Holding Sinopharm 19.3 billion in 2005 sales, with the only national distribution network in the country share of the first, huge return on investment, the recent formation of the company is technically double bottom pattern, afternoon break pulled around the corner, could focus on concern.
Doctor? Circulation revenue growth Sinopharm holding companies to invest to maintain high momentum of development. In the first half, holding Sinopharm achieved 10.92 billion yuan in sales revenue, an increase of 17.40% and net profit of 83.54 million yuan, an increase of 73%, the overall effect of fully embodied. In April of this year, G Fosun reached with the right Sinopharm Sinopharm Holdings capital increase with the proportion of agreement, form a Sinopharm Holding the development of strong capital support. During the reporting period, G Fosun Sinopharm Holding rapid growth of investment and to continue to maintain the status of the Chinese pharmaceutical distribution first, main business revenue of 10.92 billion yuan, an increase of 17.40% and net profit of 85.84 million yuan, an increase of 73 %; the wholesale, distribution, scale of operations in Shanghai, Beijing, Tianjin, Guangzhou, Shenzhen market the forefront.
Meanwhile, the company continues to accelerate construction of Artemisia annua Industrial Chain and improved. Independent innovative drugs - artesunate combination therapy and the adoption of the World Health Organization (WHO) certification, formally became the sole supplier of an antimalarial drugs directly after the reporting period, the company has formed a large-scale planting base, green Artemisinin extraction, synthesis and preparation capacity to be expanded. At the same time G Fosun has also further strengthened the artesunate combination therapy dosage form development and speeding up the registration of the pace of the country a high incidence of malaria is currently part of the international organizations and countries have been full supply of artesunate combination therapy. While in the first half did not show substantial growth, but according to G Fosun said, primarily with international organizations to postpone the procurement process. As an international organization to further stimulate the purchase, the company Artesunate the positive effect of certification will be further released, the latter part of growth is still to emerge.
Industry giant growth highlights the company is the most advantage of generics manufacturers, the industry figured prominently. The company has been active in developing new products through independent innovation, not only recognized by the State Ministry of Science and Shanghai Pharmaceutical Industry's only national 863 Program industrialization base, intellectual property protection is also listed as experimental units of the State Council. The company a total of 252 research projects; to obtain approval 10 clinical trials of new drugs to obtain the certificate 10 new drugs, medical devices and diagnostic products registration, 5, overseas product certification 7. A strong scientific research strength, so that the company's core competitive edge, forming a pharmaceutical manufacturing, diagnostic products, medical devices and pharmaceutical distribution four business blocks, and has more than 20 drugs enter "medical insurance directory." Additionally, the company owned 49% by Chigu Sinopharm stake, while the eastern part of the market to become dominant. Sinopharm Holding is the largest distribution businesses, a huge network value, the current sales network covers the economically developed eastern regions. Sinopharm internal enterprise integration, using the equity shares held by Sinopharm replenishment of the state-controlled, so that state-controlled to become the majority shareholder Sinopharm shares. If state-controlled listed on the future plans for its 2006 net profit of 180 million yuan of performance is expected to estimate the market value of 45 billion yuan, corresponding to the interests of Fosun bring about 20 billion; Fosun pairs of state-controlled The investment totaled about 1.1 billion.
Third-generation upstart company's acquisition of Shanghai New Energy for nearly 40% stake in supernatural power, and is expected to this part of the core assets into listed companies, so that the company has a distinctive new energy topics. Shanghai specializing in supernatural power, as a proton exchange membrane fuel cell R & D and industrialization of the enterprise, with a full set of 0.1 kilowatts -150 kW proton exchange membrane fuel cell power system integrated manufacturing technology and mass production capabilities. Shanghai god in fuel cell engineering technology, key components of the manufacturing process and processing technologies, and materials, parts localization have carried out large number of major areas of technological innovation, has achieved many important results. Now apply for China, the U.S. fuel cell technology patents 102, of which 32 have been mandated. Company's business mainly includes electrochemical, chemical, electrical, control, machinery manufacturing, etc., in the fuel cell engine systems engineering and integration, electronic control, fuel cell research and key technology and stable performance, reliability improvements in research, electrode manufacturing process and technology aspects of talent than the complete team, with strong supporting the development and implementation capacity. As Shanghai is China's third-generation god new energy hybrid leader, in restructuring the project after the completion of the acquisition, G Fosun will no doubt become the third generation of new energy sources of funds are going separate ways by the market pioneer and wide attention.
Quadratic back to a strong offensive line detection will soon be two years on the market in 2006, semi-annual disclosure of top ten shareholders in circulation, all institutional investors, compared to the previous view to increasing 6.06 percentage points. Decrease in the number of shareholders, betting slips further concentration trend. Technical perspective, the stock system, the medium-term moving averages upward divergence, the medium-term rise in the basic pattern has been established, pre-adjusted to follow the broader market fell by a big margin, the recent share price in the second position back to explore the important medium-term support has gradually stabilized, the stock has been solved for six months straight-line and 60 antennas pressure, the market outlook is expected to speed up the rise, it is recommended to focus on.
